Hanmi, LG Highlight Diabetes Pipeline Progress At EASD
This article was originally published in PharmAsia News
Executive Summary
South Korea’s Hanmi Pharmaceutical and LG Life Sciences presented progress across their diabetes pipelines at the recent annual EASD meeting, with both firms unveiling promising results from a range of studies.